HDL3, but not HDL2, stimulates plasminogen activator inhibitor-1 release from adipocytes: The role of sphingosine-1-phosphate

Journal of Lipid Research

Volumn 51, Issue 9, 2010, Pages 2619-2628

  Lee, Mi Hye ^a   Hammad, Samar M ^a   Semler, Andrea J ^a   Luttrell, Louis M ^a,b   Lopes Virella, Maria F ^a,b   Klein, Richard L ^a,b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b RALPH H JOHNSON VA MEDICAL CENTER   (United States)

Author keywords

Fibrinolysis lipoprotein; High density lipoprotein; Plasminogen activator inhibitor 1

Indexed keywords

1 [[6 (3 METHOXYESTRA 1,3,5(10) TRIEN 17BETA YL)AMINO]HEXYL] 1H PYRROLE 2,5 DIONE; 4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HIGH DENSITY LIPOPROTEIN 2; HIGH DENSITY LIPOPROTEIN 3; PLASMINOGEN ACTIVATOR INHIBITOR 1; RHO KINASE; SMALL INTERFERING RNA; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE 1 PHOSPHATE RECEPTOR;

ADIPOCYTE; ANIMAL CELL; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; ELECTROSPRAY MASS SPECTROMETRY; FIBRINOLYSIS; GENE SILENCING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

3T3-L1 CELLS; ADIPOCYTES; ANIMALS; CERAMIDES; HUMANS; LIPOPROTEINS, HDL2; LIPOPROTEINS, HDL3; LYSOPHOSPHOLIPIDS; MICE; PLASMINOGEN ACTIVATOR INHIBITOR 1; RECEPTORS, LYSOSPHINGOLIPID; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SPHINGOLIPIDS; SPHINGOSINE;

EID: 77956866788     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M003988     Document Type: Article

References (51)

1. Kohler, H. P., and P. J. Grant. 2000. Plasminogen activator inhibitor type 1 and coronary artery disease. N. Engl. J. Med. 342: 1792-1801.
2. Tsantes, A. E., G. K. Nikolopoulos, P. G. Bagos, E. Rapti, G. Mantzios, V. Kapsimali, and A. Travlou. 2007. Association between the plasminogen activator inhibitor-1 4G/5G polymorphism and venous thrombosis. A meta-analysis. Thromb. Haemost. 97: 907-913.
3. Lundgren, C. H., S. L. Brown, T. K. Nordt, B. E. Sobel, and S. Fujii. 1996. Elaboration of type-1 plasminogen activator inhibitor from adipocytes. A potential pathogenetic link between obesity and cardiovascular disease. Circulation. 93: 106-110.
4. Hamsten, A., U. de Faire, G. Walldius, G. D. Szamosi, C. Landou, M. Blomback, and B. Wiman. 1987. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet. 2: 3-9. (Pubitemid 17083665)
5. Le Lay, S., I. Lefère, C. Trautwein, I. Dugail, and S. Krief. 2002. Insulin and sterol-regulatory element-binding protein-1c (SREBP-1C) regulation of gene expression in 3T3-L1 adiopcytes. Identification of CCAAT/enhancer-binding protein beta as an SREBP-1C target. J. Biol. Chem. 277: 35625-35634.
6. Morange, P. E., M. C. Alessi, M. Verdier, D. Casanova, G. Magalon, and I. Juhan-Vague. 1999. PAI-1 produced ex vivo by human adipose tissue is relevant to PAI-1 blood level. Arterioscler. Thromb. Vasc. Biol. 19: 1361-1365.
7. Samarakoon, R., S. P. Higgins, C. E. Higgins, and P. J. Higgins. 2008. TGF-beta1-induced plasminogen activator inhibitor-1 expression in vascular smooth muscle cells requires pp60(c-src)/EGFR(Y845) and Rho/ROCK signaling. J. Mol. Cell. Cardiol. 44: 527-538.
8. Nakakuki, T., M. Ito, H. Iwasaki, Y. Kureishi, R. Okamoto, N. Moriki, M. Kongo, S. Kato, N. Yamada, N. Isaka, et al. 2005. Rho/Rho-kinase pathway contributes to C-reactive protein-induced plasminogen activator inhibitor-1 expression in endothelial cells. Arterioscler. Thromb. Vasc. Biol. 25: 2088-2093.
9. Takeda, K., T. Ichiki, T. Tokunou, N. Iino, S. Fujii, A. Kitabatake, H. Shimokawa, and A. Takeshita. 2001. Critical role of Rho-kinase and MEK/ERK pathways for angiotensin II-induced plasminogen activator inhibitor type-1 gene expression. Arterioscler. Thromb. Vasc. Biol. 21: 868-873.
10. Alessi, M. C., I. Juhan-Vague, T. Kooistra, P. J. Declerck, and D. Collen. 1988. Insulin stimulates the synthesis of plasminogen activator inhibitor 1 by the human hepatocellular cell line Hep G2. Thromb. Haemost. 60: 491-494.
11. Kooistra, T., P. J. Bosma, H. A. Tons, A. P. van den Berg, P. Meyer, and H. M. Princen. 1989. Plasminogen activator inhibitor 1: biosynthesis and mRNA level are increased by insulin in cultured human hepatocytes. Thromb. Haemost. 62: 723-728.
12. Stiko-Rahm, A., B. Wiman, A. Hamsten, and J. Nilsson. 1990. Secretion of plasminogen activator inhibitor-1 from cultured human umbilical vein endothelial cells is induced by very low density lipoprotein. Arteriosclerosis. 10: 1067-1073.
13. Bryan, L., B. S. Paugh, D. Kapitonov, K. M. Wilczynska, S. M. Alvarez, S. K. Singh, S. Milstien, S. Spiegel, and T. Kordula. 2008. Sphingosine-1- phosphate and interleukin-1 independently regulate plasminogen activator inhibitor-1 and urokinase-type plasminogen activator receptor expression in glioblastoma cells: implications for invasiveness. Mol. Cancer Res. 6: 1469-1477.
14. Spiegel, S., and S. Milstien. 2003. Sphingosine-1-phosphate: an enigmatic signaling lipid. Nat. Rev. Mol. Cell Biol. 4: 397-407.
15. Hla, T. 2004. Physiological and pathological actions of sphingosine 1-phosphate. Semin. Cell Dev. Biol. 15: 513-520.
16. Alvarez, S. E., S. Milstien, and S. Spiegel. 2007. Autocrine and paracrine roles of sphingosine-1-phosphate. Trends Endocrinol. Metab. 18: 300-307.
17. Watterson, K., H. Sankala, S. Milstien, and S. Spiegel. 2003. Pleiotropic actions of sphingosine-1-phosphate. Prog. Lipid Res. 42: 344-357.
18. Takuwa, Y., Y. Okamoto, K. Yoshioka, and N. Takuwa. 2008. Sphingosine-1-phosphate signaling and biological activities in the cardiovascular system. Biochim. Biophys. Acta. 1781: 483-488.
19. Rosen, H., P. J. Gonzalez-Cabrera, M. G. Sanna, and S. Brown. 2009. Sphingosine 1-phosphate receptor signaling. Annu. Rev. Biochem. 78: 743-768.
20. Okajima, F. 2002. Plasma lipoproteins behave as carriers of extracellular sphingosine 1-phosphate: is this an atherogenic mediator or an anti-atherogenic mediator? Biochim. Biophys. Acta. 1582: 132-137.
21. Murata, N., K. Sato, J. Kon, H. Tomura, M. Yanagita, A. Kuwabara, M. Ui, and F. Okajima. 2000. Interaction of sphingosine 1-phosphate with plasma components, including lipoproteins, regulates the lipid receptor-mediated actions. Biochem. J. 352: 809-815. (Pubitemid 32015038)
22. Kontush, A., P. Therond, A. Zerrad, M. Couturier, A. Negre-Salvayre, J. A. de Souza, S. Chantepie, and M. J. Chapman. 2007. Preferential sphingosine-1-phosphate enrichment and sphingomyelin depletion are key features of small dense HDL3 particles: relevance to antiapoptotic and antioxidative activities. Arterioscler. Thromb. Vasc. Biol. 27: 1843-1849.
23. Argraves, K. M., and W. S. Argraves. 2007. HDL serves as a S1P signaling platform mediating a multitude of cardiovascular effects. J. Lipid Res. 48: 2325-2333.
24. Hla, T. 2001. Sphingosine 1-phosphate receptors. Prostaglandins Other Lipid Mediat. 64: 135-142.
25. Bielawski, J., Z. M. Szulc, Y. A. Hannun, and A. Bielawska. 2006. Simultaneous quantitative analysis of bioactive sphingolipids by high-performance liquid chromatography-tandem mass spectrometry. Methods. 39: 82-91. (Pubitemid 44107706)
26. Takuwa, Y., N. Takuwa, and N. Sugimoto. 2002. The Edg family G protein-coupled receptors for lysophospholipids: their signaling properties and biological activities. J. Biochem. 131: 767-771. (Pubitemid 34717578)
27. Windh, R. T., M. J. Lee, T. Hla, S. An, A. J. Barr, and D. R. Manning. 1999. Differential coupling of the sphingosine 1-phosphate receptors Edg-1, Edg-3, and H218/Edg-5 to the G(i), G(q), and G(12) families of heterotrimeric G proteins. J. Biol. Chem. 274: 27351-27358.
28. Assmann, G., and A. M. Gotto, Jr. 2004. HDL cholesterol and protective factors in atherosclerosis. Circulation. 109 ( Suppl. 1 ): III8-III14.
29. Rader, D. J. 2003. Regulation of reverse cholesterol transport and clinical implications. Am. J. Cardiol. 92: 42J-49J.
30. Rodriguez, C., M. Gonzalez-Diez, L. Badimon, and J. Martinez-Gonzalez. 2009. Sphingosine-1-phosphate: a bioactive lipid that confers high-density lipoprotein with vasculoprotection mediated by nitric oxide and prostacyclin. Thromb. Haemost. 101: 665-673.
31. Nixon, G. F. 2009. Sphingolipids in inflammation: pathological implications and potential therapeutic targets. Br. J. Pharmacol. 158: 982-993.
32. Deutschman, D. H., J. S. Carstens, R. L. Klepper, W. S. Smith, M. T. Page, T. R. Young, L. A. Gleason, N. Nakajima, and R. A. Sabbadini. 2003. Predicting obstructive coronary artery disease with serum sphingosine-1- phosphate. Am. Heart J. 146: 62-68.
33. Faber, D. R., P. G. de Groot, and F. L. Visseren. 2009. Role of adipose tissue in haemostasis, coagulation and fibrinolysis. Obes. Rev. 10: 554-563.
34. Shaw, D. A., and D. Machaughton. 1963. Relationship between blood fibrinoytic activity and body fatness. Lancet. 1: 352-354.
35. Skurk, T., and H. Hauner. 2004. Obesity and impaired fibrinolysis: role of adipose production of plasminogen activator inhibitor-1. Int. J. Obes. Relat. Metab. Disord. 28: 1357-1364.
36. Loskutoff, D. J., and F. Samad. 1998. The adipocyte and hemostatic balance in obesity: studies of PAI-1. Arterioscler. Thromb. Vasc. Biol. 18: 1-6.
37. Alessi, M. C., P. Morange, and I. Juhan-Vague. 2000. Fat cell function and fibrinolysis. Horm. Metab. Res. 32: 504-508.
38. Janand-Delenne, B., C. Chagnaud, D. Raccah, M. C. Alessi, I. Juhan-Vague, and P. Vague. 1998. Visceral fat as a main determinant of plasminogen activator inhibitor 1 level in women. Int. J. Obes. Relat. Metab. Disord. 22: 312-317.
39. Kontush, A., S. Chantepie, and M. J. Chapman. 2003. Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress. Arterioscler. Thromb. Vasc. Biol. 23: 1881-1888.
40. Li, X. A., W. B. Titlow, B. A. Jackson, N. Giltiay, M. Nikolova-Karakashian, A. Uittenbogaard, and E. J. Smart. 2002. High density lipoprotein binding to scavenger receptor, class B, type I activates endothelial nitric-oxide synthase in a ceramide-dependent manner. J. Biol. Chem. 277: 11058-11063.
41. Yuhanna, I. S., Y. Zhu, B. E. Cox, L. D. Hahner, S. Osborne-Lawrence, P. Lu, Y. L. Marcel, R. G. Anderson, M. E. Mendelsohn, H. H. Hobbs, et al. 2001. High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase. Nat. Med. 7: 853-857.
42. Kimura, T., H. Tomura, C. Mogi, A. Kuwabara, A. Damirin, T. Ishizuka, A. Sekiguchi, M. Ishiwara, D. S. Im, K. Sato, et al. 2006. Role of scavenger receptor class B type I and sphingosine 1-phosphate receptors in high density lipoprotein-induced inhibition of adhesion molecule expression in endothelial cells. J. Biol. Chem. 281: 37457-37467.
43. Mihovilovic, M., J. B. Robinette, R. M. DeKroon, P. M. Sullivan, and W. J. Strittmatter. 2007. High-fat/high-cholesterol diet promotes a S1P receptor-mediated antiapoptotic activity for VLDL. J. Lipid Res. 48: 806-815.
44. Frias, M. A., R. W. James, C. Gerber-Wicht, and U. Lang. 2009. Native and reconstituted HDL activate Stat3 in ventricular cardiomyocytes via ERK1/2: role of sphingosine-1-phosphate. Cardiovasc. Res. 82: 313-323.
45. Kimura, T., K. Sato, A. Kuwabara, H. Tomura, M. Ishiwara, I. Kobayashi, M. Ui, and F. Okajima. 2001. Sphingosine 1-phosphate may be a major component of plasma lipoproteins responsible for the cytoprotective actions in human umbilical vein endothelial cells. J. Biol. Chem. 276: 31780-31785.
46. Kimura, T., K. Sato, E. Malchinkhuu, H. Tomura, K. Tamama, A. Kuwabara, M. Murakami, and F. Okajima. 2003. High-density lipoprotein stimulates endothelial cell migration and survival through sphingosine 1-phosphate and its receptors. Arterioscler. Thromb. Vasc. Biol. 23: 1283-1288.
47. Nofer, J. R., M. van der Giet, M. Tolle, I. Wolinska, K. von Wnuck Lipinski, H. A. Baba, U. J. Tietge, A. Godecke, I. Ishii, B. Kleuser, et al. 2004. HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J. Clin. Invest. 113: 569-581.
48. Nofer, J. R., M. Bot, M. Brodde, P. J. Taylor, P. Salm, V. Brinkmann, T. van Berkel, G. Assmann, and E. A. Biessen. 2007. FTY720, a synthetic sphingosine 1 phosphate analogue, inhibits development of atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation. 115: 501-508.
49. Nofer, J. R., B. Levkau, I. Wolinska, R. Junker, M. Fobker, A. von Eckardstein, U. Seedorf, and G. Assmann. 2001. Suppression of endothelial cell apoptosis by high density lipoproteins (HDL) and HDL-associated lysosphingolipids. J. Biol. Chem. 276: 34480-34485.
50. Hait, N. C., J. Allegood, M. Maceyka, G. M. Strub, K. B. Harikumar, S. K. Singh, C. Luo, R. Marmorstein, T. Kordula, S. Milstien, et al. 2009. Regulation of histone acetylation in the nucleus by sphingosine-1-phosphate. Science. 325: 1254-1257.
51. Kim, R. H., K. Takabe, S. Milstien, and S. Spiegel. 2009. Export and functions of sphingosine-1-phosphate. Biochim. Biophys. Acta. 1791: 692-696.